LVGN-1673

N/A

Report date: 2025/05/14 15:49:55

Base Information

Drug NameLVGN-1673

Drug Alias NameLVGN-1673

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionTransforming growth factor beta inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants +[4]

TargetsTransforming growth factor betaProgrammed death-ligand 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesLyvgen Biopharma(HK)Ltd

China Registration ClassN/A

Develop Information

Active CompaniesLyvgen Biopharma(HK)Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A